中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.03 seconds)

    POLYPEPTIDE CONSTRUCTS BINDING TO CD3
    2.
    发明申请
    POLYPEPTIDE CONSTRUCTS BINDING TO CD3 审中-公开

    公开(公告)号：WO2022096698A1

    公开(公告)日：2022-05-12

    申请号：PCT/EP2021/080859

    申请日：2021-11-08

    Applicant: AMGEN INC. ,  AMGEN RESEARCH (MUNICH) GMBH

    Inventor： RAU, Doris ,  RAUM, Tobias ,  HOFFMANN, Patrick ,  MUENZ, Markus ,  KLINGER, Matthias ,  NAEGELE, Virgine ,  WINKEL, Lisa ,  GHATTYVENKATAKRISHNA, Pavan ,  HUH, Joon Hoi ,  MCAULEY, Arnold ,  KANAPURAM, Sekhar

    IPC: C07K16/28 ,  A61P35/00

    Abstract: The invention relates to a polypeptide or polypeptide construct comprising: a binding domain binding to an extracellular epitope of the human CD3s chain comprising or consisting of a VH region and a VL region, wherein i) the VH region comprises: a CDR- H1 sequence of X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I; a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2, where Χ1 is S or Q; and X2 is D, G, K, S, or E; and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY, where ΧΊ is G, R, or A; X2 is I, L, V, or T; X3 is Y, W or F; and X4 is W, F or Y; and ii) wherein the VL region comprises: a CDR-L1 sequence of ΧΊ SSTGAVTX2X3X4YX5N, where ΧΊ is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y; and X5 is P or A; a CDR-L2 sequence of X1TX2X3X4X5X6; where Χ1 is G or A; X2 is K, D, or N; X3 is F, M or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S; and a CDR-L3 sequence of X1LWYSNX2VW, where X1 is V, A, or T; and X2 is R or L; and iii) wherein one or more of CDR sequences of the VH region of i) and/or of the VL region of ii) comprise one amino acid substitution or a combination thereof selected from X24V and X24F in CDR-H1; D15, and X116A in CDR-H2; H1, X12E, F4, and N6 in CDR-H3; and X11L and W3 in CDR-L3. The invention also relates to a polynucleotide encoding the polypeptide or polypeptide construct of the invention, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or with said vector. Moreover, the invention also provides for a process for the production of said polypeptide or polypeptide construct and a pharmaceutical composition comprising said polypeptide or polypeptide construct of the invention. Furthermore, the invention relates to medical uses of said polypeptide or polypeptide construct and kits comprising said polypeptide or polypeptide construct.

    STABLE FORMULATIONS
    4.
    发明申请
    STABLE FORMULATIONS 审中-公开
    稳定的公式

    公开(公告)号：WO2008045373A2

    公开(公告)日：2008-04-17

    申请号：PCT/US2007/021477

    申请日：2007-10-05

    Applicant: AMGEN INC. ,  MCAULEY, Arnold ,  REHDER, Douglas ,  MATSUMURA, Masazumi

    Inventor： MCAULEY, Arnold ,  REHDER, Douglas ,  MATSUMURA, Masazumi

    IPC: A61K9/20 ,  A61K31/44 ,  A61K31/5377

    CPC classification number: A61K31/44 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/5377 ,  A61K39/39591 ,  A61K47/12 ,  A61K47/26 ,  C07K16/2863 ,  C07K2317/21

    Abstract: The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a polyol and an effective amount of a therapeutic antibody. The buffer can include a salt of acetate, glutamate or succinate and the sugar or polyol can include glycerol, sucrose, trehalose or sorbitol. The therapeutic antibody can include a human antibody, a humanized antibody, a chimeric antibody, or a functional fragment thereof.

    Abstract translation: 本发明提供了包含乙酸缓冲液，谷氨酸缓冲液或pH为约4.5-7.0的琥珀酸缓冲液，至少一种包含糖或多元醇的赋形剂和有效量的治疗性抗体的制剂。 缓冲液可以包括乙酸盐，谷氨酸盐或琥珀酸盐，糖或多元醇可以包括甘油，蔗糖，海藻糖或山梨糖醇。 治疗性抗体可以包括人抗体，人源化抗体，嵌合抗体或其功能片段。

Patent Agency Ranking